Clinical trials: Pulmonary Hypertension
Pulmonary Hypertension
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT00370214
- Where
- 54 sites in United States
- Volunteers
- 3,515 people
- Sponsor
- Actelion
Chuvash Polycythemia, Cerebrovascular Disease
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease
The study will look at the risk factors for pulmonary hypertension (high blood pressure in the lungs) in children and adolescents with sickle cell anemia (SCA) and examine the role of hypoxia (oxygen shortage) in the disease.
- Conditions
- Chuvash Polycythemia, Cerebrovascular Disease, Pulmonary Hypertension, Sickle Cell Anemia
- Trial name
- NCT00495638
- Where
- 7 sites in United States, Russia
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Hypertension, Primary, 4
Serum Bio-markers in Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart.
- Trial name
- NCT04472533
- Where
- United Kingdom
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension
Anti-CD20 Antibodies for Treatment of SLE-PAH
This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent stable-dose standard medical therapy.
- Trial name
- NCT05828147
- Testing
- Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese SLE Treatment And Research Group
Hypertension, Pulmonary
The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH
Pulmonary hypertension (PH) is a progressive disease with high mortality rate, but due to the development of drugs, the prognosis of the disease has improved.
- Trial name
- NCT02647060
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Pulmonary Hypertension
Prognostic Value of Vitamin D and Intact Parathyroid Hormone (iPTH) in Pulmonary Hypertension
The aim of this observational study is to analyse the prognostic value of 25(OH)-vitamin D, iPTH and other serum biomarkers in patients with pulmonary hypertension.
- Trial name
- NBHAP (NCT06872710)
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Universidad Complutense de Madrid
Pulmonary Hypertension
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05918458
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Pulmonary Embolism
Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism
Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment…
- Trial name
- CONTACT-SPE (NCT02132689)
- Testing
- Actilyse (Thrombolytic therapy), Heparine (Standard anticoagulation therapy)
- Where
- 2 sites in Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Ostrava
Pulmonary Arterial Hypertension
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
- Trial name
- IMPRES (NCT00902174)
- Testing
- imatinib mesylate
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
PAH
Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, >95% v/v), as an adjunct to standard-of-care…
- Trial name
- OMEGA-PAH (NCT07697235)
- Testing
- OMega 3
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Pandemic, Diabetes
Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19
The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24…
- Conditions
- COVID-19 Pandemic, Diabetes, Hypertension, Cardiac Disease
- Trial name
- NCT06231225
- Testing
- Incentive Spirometer respiratory training
- Volunteers
- 100 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension (PAH)
Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes…
- Trial name
- NCT07082933
- Testing
- Standard medical treatment
- Volunteers
- 5,000 people
- Sponsor
- Xijing Hospital
Chronic Thromboembolic Pulmonary Hypertension
Identification of Heritable CTEPH
Some patients who have blood clots come down with a life-threatening condition known as Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which is high blood pressure only in the arteries of the lungs.
- Trial name
- NCT03579862
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Intermountain Health Care, Inc.
Type 2 Diabetes Mellitus, Lung Diseases, Obstructive
Integration of Guidelines for Comorbidities
Introduction: in the course of the research, the investigators will develop a decision-support system (comorbidity-DSS) consisting (1) a knowledge base (KB) consisting of (a) computer-interpretable clinical guidelines for type 2…
- Conditions
- Type 2 Diabetes Mellitus, Lung Diseases, Obstructive, Osteoporosis, Hypertension
- Trial name
- NCT02928666
- Testing
- DSS for mitigating interactions between recommendations
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Pulmonary Arterial Hypertension
Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography
The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT).
- Trial name
- NCT01829672
- Testing
- Dual-energy computed tomography investigation
- Where
- Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.